Evidence map›Paper›PMID 38148041›Full record

ArticleIn vivo (Athens, Greece)

A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer.

Tetsuya Kubota, Mizu Sakai, Kazuki Anabuki, Kazufumi Takamatsu, Kenichi Mukaida, Kana Kobayashi, Takuji Yamagami, Akihito Yokoyama

Open access · diamondAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tetsuya KubotaDepartment of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School, Kochi, Japan kubotat@kochi-u.ac.jp.
Mizu SakaiDepartment of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School, Kochi, Japan.
Kazuki AnabukiDepartment of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School, Kochi, Japan.
Kazufumi TakamatsuDepartment of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School, Kochi, Japan.
Kenichi MukaidaDepartment of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School, Kochi, Japan.
Kana KobayashiDepartment of Radiology, Kochi University, Kochi Medical School, Kochi, Japan.
Takuji YamagamiDepartment of Radiology, Kochi University, Kochi Medical School, Kochi, Japan.
Akihito YokoyamaDepartment of Respiratory Medicine and Allergology, Kochi University, Kochi Medical School, Kochi, Japan.
Kōchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis study aimed to evaluate the safety and recommended dose of nab-paclitaxel in combination with carboplatin and thoracic radiotherapy for locally advanced non-small cell lung cancer (NSCLC). PATIENTS AND

methodsNab-paclitaxel was administered weekly with escalating doses, combined with carboplatin area under the curve (AUC) 2 and concurrent standard thoracic radiotherapy. Escalating doses of nab-paclitaxel were as follows: level 0, 30 mg/m

conclusionConcurrent chemoradiotherapy with weekly nab-paclitaxel (40 mg/m

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinHumansPaclitaxel130-nm albumin-bound paclitaxelAlbuminsCarboplatinPaclitaxelcarboplatinconcurrent chemoradiotherapynab-paclitaxelNon-small cell lung cancerphase I

Identifiers

PMID38148041
PMCPMC10756434
OpenAlexW4390236544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.